Cencora, Inc. (COR) — 分析摘要
Cencora, Inc.（COR）的市值为62.03十亿美元，最近一年的营收同比增长了+9.3%。净利润率为0.5%。当前市盈率为23.6倍。
核心要点
- 营收同比变化+9.3%
- 净利润率0.5%
- 市盈率23.6倍
与WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES板块的其他公司相比，COR的营收增长为+9.3%，市盈率为23.6倍。
Cencora, Inc. (COR)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
流动比率为 0.93x — 流动负债超过流动资产
D/E 为 3.6x — 财务杠杆偏高
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
行业
WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
员工人数
51,000
总部
CONSHOHOCKEN, PA
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$2.40
股息收益率
0.74%
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。